Ectoline 10% w/v Spot-On Solution for Small Dogs

Main information

  • Trade name:
  • Ectoline 10% w/v Spot-On Solution for Small Dogs
  • Pharmaceutical form:
  • Spot-on solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Ectoline 10% w/v Spot-On Solution for Small Dogs
    Netherlands
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • fipronil
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0307/001
  • Authorization date:
  • 08-11-2011
  • EU code:
  • UK/V/0307/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:August2011

AN:00315/2010

Page1of7

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

FIPROLINE67mgspot-onsolutionforsmalldogs

(NL:EXILFIPROLINE)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

One0.67mlpipettecontains:

Activesubstance:

Fipronil 67mg

Excipients:

ButyhydroxyanisoleE3200.134mg/pipette

ButylhydroxytolueneE3210.067mg/pipette

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Spot-onsolution.

Clear,colourlesstoyellowsolution.

4. CLINICALPARTICULARS

4.1Targetspecies

Dogs.

4.2Indicationsforuse

Treatmentofflea(Ctenocephalidesspp.)andtick(Dermacentorreticulatus)

infestations.

Insecticidalefficacyagainstnewinfestationswithadultfleaspersistsforupto8

weeks.

Theproducthasapersistentacaricidalefficacyforupto4weeksagainstticks

(Rhipicephalussanguineus,Ixodesricinus,Dermacentorreticulatus).Ifticksof

somespecies(RhipicephalussanguineusandIxodesricinus)arepresentwhen

theproductisapplied,alltheticksmaynotbekilledwithinthefirst48hoursbut

theymaybekilledwithinaweek.

TheproductcanbeusedaspartofatreatmentstrategyforthecontrolofFlea

AllergyDermatitis(FAD)wherethishasbeenpreviouslydiagnosedbyaveterinary

surgeon.

Revised:August2011

AN:00315/2010

Page2of7

4.3Contraindications

Donotuseonpuppieslessthan2monthsoldand/orweighinglessthan2kginthe

absenceofavailabledata.

Donotuseonsick(e.g.systemicdiseases,fever…)orconvalescentanimals.

Donotuseinrabbits,asadversereactionsandevendeathcouldoccur.

Thisproductisspecificallydevelopedfordogs.Donotuseincats,asthiscould

leadtooverdosing.

Donotuseincasesofhypersensitivitytotheactivesubstanceortoanyof

excipients.

4.4Specialwarningsforeachtargetspecies

Shampooinganhourpriortotreatmentdoesnotaffecttheefficacyoftheproduct

againstfleas.

Bathing/immersioninwaterwithintwodaysafterapplicationoftheproductshould

beavoided.Weeklyimmersioninwaterforoneminutereducestheperiodof

persistentinsecticidalefficacyagainstfleasbyoneweek.

Theproductdoesnotpreventticksfromattachingtotheanimals.Iftheanimalhas

beentreatedpriortoexposuretotheticks,thetickswillbekilledinthefirst24-48

hoursafterattachment.Thiswillusuallybepriortoengorgement,minimisingbut

notexcludingtheriskoftransmissionofdiseases.Oncedead,tickswilloftendrop

offtheanimal,butanyremainingticksmayberemovedwithagentlepull.

Fleasfrompetsofteninfesttheanimal'sbasket,beddingandregularrestingareas

suchascarpetsandsoftfurnishingswhichshouldbetreated,incaseofmassive

infestationandatthebeginningofthecontrolmeasures,withasuitableinsecticide

andvacuumedregularly.

WhenusedaspartofastrategyforthetreatmentofFleaAllergyDermatitis,

monthlyapplicationstotheallergicpatientandtootherdogsinthehouseholdare

recommended.

Foroptimalcontroloffleainfestationinmulti-pethousehold,alldogsandcatsin

thehouseholdshouldbetreatedwithasuitableinsecticide.

4.5Specialprecautionsforuse

i. Specialprecautionsforuseinanimals

Animalsshouldbeweighedaccuratelypriortotreatment.

Avoidcontactwiththeanimal’seyes.Inthecaseofaccidentaleyecontact,

immediatelyandthoroughlyflushtheeyeswithwater.

Revised:August2011

AN:00315/2010

Page3of7

Itisimportanttomakesurethattheproductisappliedtoanareawherethe

animalcannotlickitoffandtomakesurethatanimalsdonotlickeachother

followingtreatment

Donotapplytheproductonwoundsordamagedskin.

ii.Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Thisproductcancausemucousmembraneandeyeirritation.Therefore,

contactbetweentheproductandthemouthoreyesshouldbeavoided.

Inthecaseofaccidentaleyecontact,immediatelyandthoroughlyflushthe

eyeswithwater.Ifeyeirritationpersistsseekmedicaladviceandshowthe

packageleafletorthelabeltothephysician.

Donotsmoke,drinkoreatduringapplication.

Avoidcontentscomingintocontactwiththefingers.Ifthisoccurs,wash

handswithsoapandwater.Washhandsafteruse.

Animalsoroperatorswithaknownhypersensitivitytofipronilorexcipients

(seesection6.1.)shouldavoidcontactwiththeveterinarymedicinalproduct.

Treatedanimalsshouldnotbehandleduntiltheapplicationsiteisdry,and

childrenshouldnotbeallowedtoplaywithtreatedanimalsuntilthe

applicationsiteisdry.Itisthereforerecommendedthatanimalsarenot

treatedduringtheday,butshouldbetreatedduringtheearlyevening,and

thatrecentlytreatedanimalsshouldnotbeallowedtosleepwithowners,

especiallychildren.

iii.Otherprecautions

Fipronilmayadverselyaffectaquaticorganisms.Dogsshouldnotbeallowed

toswiminwatercoursesfor2daysafterapplication.

Theproductmayhaveadverseeffectsonpainted,varnishedorother

householdsurfacesorfurnishings.

4.6Adversereactions(frequencyandseriousness)

Iflickingoccurs,abriefperiodofhypersalivationmaybeobservedduemainlyto

thenatureofthecarrier.

Amongtheextremelyraresuspectedadversereactions,transientcutaneous

reactionsontheapplicationsite(skindiscoloration,localalopecia,pruritus,

erythema)andgeneralpruritusoralopeciahavebeenreportedafteruse.

Exceptionally,hypersalivation,reversibleneurologicsymptoms(hyperesthesia,

depression,nervoussymptoms),vomitingorrespiratorysymptomshavebeen

observedafteruse.

4.7Useduringpregnancyandlactation

Laboratorystudiesusingfipronilhavenotshownanyevidenceofteratogenicor

embryotoxiceffect.Studieshavenotbeencarriedoutwiththisproductinpregnant

Revised:August2011

AN:00315/2010

Page4of7

andlactatingbitches.Useinpregnancyandlactationonlyinaccordancewith

professionalveterinaryadviceandabenefit/riskassessment.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9Amountstobeadministeredandadministrationroute

Routeofadministrationanddosage:

Externaluseonly.

Administerbytopicalapplicationtotheskinaccordingtothebodyweightas

follows:

1pipetteof0.67mlperdogweighingover2kgandupto10kgbodyweight.

Methodofadministration:

Thermoformedpipettes:

Holdthepipetteupright.Tapthenarrowpartofthepipettetoensurethatthe

contentsarewithinthemainbodyofthepipette.Breakthesnap-offtopofthespot-

onpipettealongthescoredline.

Partthepet’scoatuntilitsskinisvisible.Placethetipofthepipettedirectly

againstthebaredskinandsqueezegentlyseveraltimestoemptyitscontents

Repeatthisprocedureatoneortwodifferentpointsalongthepet’sback.

Polypropylenepipettes:

Removethepipettefromtheblisterpackaging.Holdthepipetteinanupright

position,twistandpullthecapoff.Turnthecaparoundandplacetheotherendof

thecapbackonthepipette.Twistthecaptobreaktheseal,thenremovethecap

fromthepipette.

Partthepet’scoatuntilitsskinisvisible.Placethetipofthepipettedirectly

againstthebaredskinandsqueezegentlyseveraltimestoemptyitscontents.

Repeatthisprocedureatoneortwopointsalongthepet’sback.

Revised:August2011

AN:00315/2010

Page5of7

Itisimportanttomakesurethattheproductisappliedtoanareawheretheanimal

cannotlickitoff,andtomakesurethatanimalsdonotlickeachotherfollowing

treatment.

Careshouldbetakentoavoidexcessivewettingofthehairwiththeproductsince

thiswillcauseastickyappearanceofhairsatthetreatmentspot.However,should

thisoccur,itwilldisappearwithin24hourspostapplication.

Treatmentschedule:

Foroptimalcontroloffleaand/ortickinfestationthetreatmentschedulecanbe

basedonthelocalepidemiologicalsituation.

Intheabsenceofsafetystudies,theminimumtreatmentintervalis4weeks.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Noadverseeffectswereobservedintargetanimalsafetystudiesin2month-old

puppies,growingdogsanddogsweighingabout2kgtreatedwiththetherapeutic

doseonfiveconsecutivedays.Theriskofadverseeffects(seesection4.6)may

increaseincasesofoverdose.

4.11Withdrawalperiod

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Ectoparasiticidesfortopicaluse.

ATCvetcode:QP53AX15

5.1Pharmacodynamicproperties

Fipronilisaninsecticideandacaricidebelongingtothephenylpyrazolefamily.It

actsbyinhibitingtheGABAcomplex,bindingtothechloridechannelandthereby

blockingpre-andpost-synaptictransferofchlorideionsacrosscellmembranes.

Thisresultsinuncontrolledactivityofthecentralnervoussystemanddeathof

insectsoracarids.

Fipronilexhibitsaninsecticidalandacaricidalactivityagainstfleas

(Ctenocephalidesspp),ticks(Rhipicephalusspp,Dermacentorspp,Ixodesspp

includingIxodesricinus)inthedog.

Fleaswillbekilledwithin24h.Tickswillusuallybekilledwithin48haftercontact

withFipronil,howeverifticksofsomespecies(Rhipicephalussanguineusand

Ixodesricinus)arealreadypresentwhentheproductisapplied,alloftheticks

maynotbekilledwithinthefirst48hours.

5.2Pharmacokineticparticulars

Revised:August2011

AN:00315/2010

Page6of7

Fipronilismainlymetabolisedtoitssulfonederivative(RM1602),whichalso

possessesinsecticidalandacaricidalproperties.Theconcentrationsoffipronilon

thehairdecreasewithtime.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

ButylhydroxyanisoleE320

ButylhydroxytolueneE321

Benzylalcohol

Diethyleneglycolmonoethylether

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years.

6.4.Specialprecautionsforstorage

Storebelow30°C.Storeinadryplace.Storeintheoriginalpackage.

6.5Natureandcompositionofimmediatepackaging

Thermoformedpipettes:Whiteortransparentmulti-layerplasticsingle-dose

pipettescontaininganextractiblevolumeof0.67ml.

Theinternallayersincontactwiththeproductaremadeofpolyacrylonitrile-

methacrylate.Thewhiteexternalcomplexiscomposedofpolypropylene/cyclic

olefinecopolymer/polypropylene.

Boxesof1,2,3,4,6,8,12,24,30,60,90or150pipettes.

Polypropylenepipettes:Whitepolypropylenesingle-dosepipettescontainingan

extractiblevolumeof0.67mlpackagedinuncolouredplasticblistercomposedof

polypropylene/cyclicolefinecopolymer/polypropyleneclosedbyheatsealingwith

athermosealablelacqueredaluminiumfoilandplacedinacartonboxorblister

card.

Blistercardsorboxesof1,2,3,4,6,8,12,24,30,60,90or150pipettes.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

Revised:August2011

AN:00315/2010

Page7of7

Fipronilmayadverselyaffectaquaticorganisms.Donotcontaminateponds,

waterwaysorditcheswiththeproductoremptycontainer.

7. MARKETINGAUTHORISATIONHOLDER

FRANCODEX

ère

avenue –2065m–L.I.D.

06516Carros

FRANCE

+33(0)492087304

+33(0)492087348

8. MARKETINGAUTHORISATIONNUMBER

Vm 32991/4002

9. DATEOFFIRSTAUTHORISATION

Date:16April2009

10.DATEOFREVISIONOFTHETEXT

Date:August2011

27-11-2018

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

Published on: Mon, 26 Nov 2018 Abstract In response to the EFSA call New approaches in identifying and characterizing microbial and chemical hazards, the project INNUENDO (https://sites.google.com/site/theinnuendoproject/) aimed to design an analytical platform and standard procedures for the use of whole‐genome sequencing in surveillance and outbreak investigation of food‐borne pathogens. The project firstly attempted to identify existing flaws and needs, and then to provide applicable cross‐sectorial ...

Europe - EFSA - European Food Safety Authority Publications

22-10-2018

Promise Pharmacy Issues Voluntary Nationwide Recall of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% Sterile Due to Small Particulate Floating in the Solution

Promise Pharmacy Issues Voluntary Nationwide Recall of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% Sterile Due to Small Particulate Floating in the Solution

Promise Pharmacy is voluntarily recalling one lot of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% sterile, 3ml vials, to the patient consumer level. The product has been found to have unidentified small particulate floating in the solution.

FDA - U.S. Food and Drug Administration

11-9-2018

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Antimicrobial resistance (AMR) represents a major challenge for Public Health and the scientific community, and requires immediate and drastic solutions. Acquired resistance to certain antimicrobials is already widespread to such an extent that their efficacy in the treatment of certain life‐threatening infections is already compromised. To date, the emergence and spread of AMR has been attributed to the use, misuse or indiscriminate use of antibiotics as th...

Europe - EFSA - European Food Safety Authority Publications

1-9-2018

Spodoptera frugiperda partial risk assessment

Spodoptera frugiperda partial risk assessment

Published on: Fri, 31 Aug 2018 00:00:00 +0200 EFSA was asked for a partial risk assessment of Spodoptera frugiperda for the territory of the EU focussing on the main pathways for entry, factors affecting establishment, risk reduction options and pest management. As a polyphagous pest, five commodity pathways were examined in detail. Aggregating across these and other pathways, we estimate that tens of thousands to over a million individual larvae could enter the EU annually on host commodities. Instigat...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 10 Aug 2018 00:00:00 +0200 This scientific opinion of the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) deals with the safety evaluation of the recycling process General Plastic (EU register No RECYC153), which is based on the Starlinger Decon technology. The decontamination efficiency of the process was demonstrated by a challenge test. The input of this process is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes orig...

Europe - EFSA - European Food Safety Authority Publications

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

30-4-2018

Stonewall Kitchen Voluntarily Recalls a Limited Amount of Basil Pesto Aioli due to Mislabeling and Undeclared Presence of the Dairy Allergen, Egg

Stonewall Kitchen Voluntarily Recalls a Limited Amount of Basil Pesto Aioli due to Mislabeling and Undeclared Presence of the Dairy Allergen, Egg

Stonewall Kitchen is voluntarily recalling a limited amount of 10.25oz Basil Pesto Aioli with an Enjoy By date of 28 Sep 2019 which may contain the undeclared allergen egg, as we may have inadvertently placed the label for our Basil Pesto on a small portion of our most recent production run.

FDA - U.S. Food and Drug Administration

There are no news related to this product.